[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100545287":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":22,"responsibleParty":86,"collaborators":88,"id":92,"slug":93,"hasResults":94,"nctId":95,"briefTitle":96,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":94,"sex":99,"minAge":100,"maxAge":7,"enrollmentInfo":101,"targetDuration":7,"studyType":104,"phases":7,"briefSummary":105,"conditions":106,"keywords":108,"overallStatus":25,"whyStopped":7,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":122},{"fullName":5,"class":6},"Instituto de Investigación Biomédica de Salamanca","OTHER",null,[9],{"name":10,"affiliation":5,"role":11},"María Díez Campelo, PhD MD","STUDY_CHAIR",[13,18],{"name":10,"role":14,"phone":15,"phoneExt":16,"email":17},"CONTACT","+34 923 29 11 00","55418","mdiezcampelo@usal.es",{"name":19,"role":14,"phone":20,"phoneExt":7,"email":21},"Mónica del Rey González, PhD","+34 923 29 48 12","mdelrey@usal.es",[23,43,56,70],{"facility":24,"status":25,"city":26,"state":27,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"Fundación Instituto de Investigación Germans Trias i Puyol","RECRUITING","Badalona","Barcelona","08916","Spain","ES",{"type":32,"coordinates":33},"Point",[34,35],2.24741,41.45004,{"lat":35,"lon":34},[38],{"name":39,"role":14,"phone":40,"phoneExt":41,"email":42},"Francesc Solé, PhD","935 57 28 06","4040","fsole@carrerasresearch.org",{"facility":44,"status":25,"city":27,"state":7,"zip":45,"country":29,"countryCode":30,"cosmosGeoPoint":46,"geoPoint":50,"contacts":51},"Hospital Universitario Vall d´Hebron","08035",{"type":32,"coordinates":47},[48,49],2.15899,41.38879,{"lat":49,"lon":48},[52],{"name":53,"role":14,"phone":54,"phoneExt":7,"email":55},"David Valcárcel Ferreiras, PhD","934 89 30 00","dvalcarcel@vhio.net",{"facility":57,"status":25,"city":58,"state":7,"zip":59,"country":29,"countryCode":30,"cosmosGeoPoint":60,"geoPoint":64,"contacts":65},"Clínica Universitaria de Navarra","Pamplona","31008",{"type":32,"coordinates":61},[62,63],-1.64323,42.81687,{"lat":63,"lon":62},[66],{"name":67,"role":14,"phone":68,"phoneExt":7,"email":69},"Felipe López Cardoso, PhD","848 42 87 00","fprosper@unav.es",{"facility":71,"status":25,"city":72,"state":7,"zip":73,"country":29,"countryCode":30,"cosmosGeoPoint":74,"geoPoint":78,"contacts":79},"Complejo Asistencial Universitario de Salamanca","Salamanca","37007",{"type":32,"coordinates":75},[76,77],-5.66388,40.96882,{"lat":77,"lon":76},[80,82],{"name":81,"role":14,"phone":15,"phoneExt":16,"email":17},"María Díez Campelo, PhD",{"name":83,"role":14,"phone":15,"phoneExt":84,"email":85},"Sandra Muntión Olave, PhD","55015","terapiacelular@usal.es",{"type":87,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[89],{"name":90,"class":91},"Carlos III Health Institute","OTHER_GOV","100545287","unified-platform-for-a-better-integral-evaluation-of-myelodysplastic-syndromes-in-spain-strategy-for-unraveling-personalized-genomic-medicine-in-public-health-system-umbrella-summa-100545287",false,"NCT06379945","Unified platforM for a Better integRal Evaluation of MyeLodyspLastic Syndromes in SpAin-Strategy for Unraveling Personalized genoMic Medicine in Public heAlth System (UMBRELLA-SUMMA)","UMBRELLA-SUMMA","Inclusion Criteria:\n\n* Patients over 18 years old\n* Patients with a confirmed diagnosis of MDS by cytogenetics and\u002For morphological analysis\n* Patients with complete clinical data\n* Patients who sign the informed consent\n\nExclusion Criteria:\n\n* Patients under 18 years old\n* Patients who do not sign the informed consent","ALL","18 Years",{"count":102,"type":103},300,"ESTIMATED","OBSERVATIONAL","Myelodysplastic Syndromes (MDS) are heterogeneous clonal diseases characterized by difficult diagnosis, complex prognostic stratification and unsatisfactory treatment. Based on that, UMBRELLA SUMMA aims to provide better clinical management and personalized medicine to MDS patients in Spain through improving diagnosis (1), prognosis (2 and 3), and treatment (2), and facilitating future investigations (4) of the disease.\n\nMore concretely, we propose: 1. The application of new technologies such as Optical Genome Mapping (OGM) in the diagnosis of those MDS cases whose cytogenetic alterations cannot be identify by other methods, as well as the implementation of this technology using peripheral blood avoiding more invasive methods for patients. 2. To provide all Spanish Group of MDS (GESMD) members who require it with the newly prognostic stratification of their patients (IPSS-M) by making Next Generation Sequencing (NGS) accessible for all of them. 3. Validate and improve a new prognostic system (AIPSS-MDS) previously developed within the GESMD, thanks to artificial intelligence, one of the tools with the most projection in the field of medicine currently. 4. To build and register ISCIII collections of cells, genetic material and\u002For plasma from all prospective MDS patients.\n\nOn the other hand, the dynamics of coexisting mutations in a specific context of chromosomal abnormalities could be defining the clinical fate of each patient. Based on that, the IBSAL team recently proposed three models of MDS evolution based on NGS data from three different cytogenetic subgroups: normal karyotype, trisomy 8 and 5q deletion. The IBSAL proposal aims to deepen into the pathophysiological mechanisms of MDS evolution in these three models through in vitro and in vivo functional studies and single-cell multiomics approaches.",[107],"Myelodysplastic Syndromes",[109,110,111,112],"Optical Genome Mapping","Next Generation Sequencing","Artificial Intelligence","Clonal evolution","2025-04-29",{"date":115,"type":116},"2025-05-02","ACTUAL",{"date":118,"type":116},"2024-01-01",{"date":120,"type":103},"2026-12-31",{"name":5,"class":6},4]